Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10792371 | 0.81 | POLB (0.46) | ALDH1A1HTTPOLBLMNAMAPT | |
| SCHEMBL11105640 | 0.81 | KDM4E (0.60) | ALDH1A1HTTGAAPOLBTP53 | |
| SCHEMBL12892210 | 0.79 | JAK2 (0.55) | ALDH1A1POLBMAPTKMT2A | |
| SCHEMBL2662445 | 0.79 | ALPL (0.61) | ALDH1A1HTTPOLBTP53L3MBTL1 | |
| SCHEMBL1250218 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GAAPOLBL3MBTL1MAPT | |
| SCHEMBL3788576 | 0.79 | POLB (0.55) | GAAPOLBLMNAKMT2A | |
| SCHEMBL10790321 | 0.79 | POLB (0.44) | ALDH1A1HTTPOLBMAPTKMT2A | |
| SCHEMBL11561215 | 0.79 | ACMSD (0.50) | POLBKMT2AKDM4E | |
| SCHEMBL151398 | 0.79 | NPC1 (0.50) | HTTKMT2A | |
| SCHEMBL11156635 | 0.78 | CNR2 (0.52) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | disclosed |
| EP-2212303-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068509-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286149-A1 | NOVEL BENZAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCNA2, KCNJ2, KCNB2 | ALDH1A1 2385/4885CHRNB2 332/4885CHRNB4 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.